← brief for 2026-09-03 · Slowing decline

PRO/CON debate: nonsteroidal versus steroidal mineralocorticoid receptor antagonists in chronic kidney disease: progress, pragmatism, and remaining uncertainties.

Key takeaways

Two sides argue over which kind of hormone-blocking drug is better for chronic kidney disease. The older drugs, spironolactone and eplerenone, cut protein leaking into the urine but push up potassium and cause hormone side effects, which has limited their use. The newer type, such as finerenone, was designed to keep the benefit with fewer of those problems. This is a debate piece weighing evidence that already exists, so it reports no new results.

Who did this work

Agarwal R · Vogt L · Floege J · Zoccali C

Source

Article · PubMed, the drug frontier · 2026 Aug 17
https://pubmed.ncbi.nlm.nih.gov/42682722/